Literature DB >> 27138601

No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery.

Carsten Dirksen1,2, Aleksander Eiken3,4, Kirstine N Bojsen-Møller3,4, Maria S Svane3,4, Christoffer Martinussen3,4, Nils B Jørgensen3,4, Jens J Holst4,5, Sten Madsbad3.   

Abstract

Postprandial hyperinsulinemia characterizes Roux-en-Y gastric bypass (RYGB) and sometimes leads to reactive hypoglycemia. We prospectively evaluated changes in beta cell function in seven RYGB-operated patients with a median follow-up of 2.9 years with hyperglycemic clamps and oral glucose tolerance tests (OGTTs). Three years after RYGB, weight loss was 26 % and insulin sensitivity had improved. Insulin secretion during clamp experiments was largely unchanged compared to before surgery. In contrast, insulin secretion in response to the OGTTs doubled when evaluated by the disposition index and 2-h plasma glucose declined to a mean of 3.3 ± 0.3 mmol/l postoperatively. Our findings indicate that intrinsic beta cell function remains unchanged in glucose-tolerant patients even years after RYGB, while altered gut-islet regulation drive risk of postprandial hyperinsulinemic hypoglycemia.

Entities:  

Keywords:  Bariatric surgery; Glucagon; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Insulin resistance; Insulin secretion rate; Obesity

Mesh:

Substances:

Year:  2016        PMID: 27138601     DOI: 10.1007/s11695-016-2197-x

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  10 in total

Review 1.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

2.  ISEC: a program to calculate insulin secretion.

Authors:  R Hovorka; P A Soons; M A Young
Journal:  Comput Methods Programs Biomed       Date:  1996-08       Impact factor: 5.428

3.  Preoperative β-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery.

Authors:  Michael Taulo Lund; Merethe Hansen; Stinna Skaaby; Sina Dalby; Mikael Støckel; Andrea Karen Floyd; Karsten Bech; Jørn Wulff Helge; Jens Juul Holst; Flemming Dela
Journal:  J Physiol       Date:  2015-06-17       Impact factor: 5.182

4.  Hypoglycemia after Roux-en-Y gastric bypass: the BOLD experience.

Authors:  Hafiz Sarwar; William H Chapman; John R Pender; Andrada Ivanescu; Almond J Drake; Walter J Pories; Moahad S Dar
Journal:  Obes Surg       Date:  2014-07       Impact factor: 4.129

5.  GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects.

Authors:  Rosa Morínigo; Antonio M Lacy; Roser Casamitjana; Salvadora Delgado; Ramon Gomis; Josep Vidal
Journal:  Obes Surg       Date:  2006-12       Impact factor: 4.129

6.  Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.

Authors:  Carsten Dirksen; Kirstine N Bojsen-Møller; Nils B Jørgensen; Siv H Jacobsen; Viggo B Kristiansen; Lars S Naver; Dorte L Hansen; Dorte Worm; Jens J Holst; Sten Madsbad
Journal:  Diabetologia       Date:  2013-09-19       Impact factor: 10.122

7.  Long-term effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects.

Authors:  Josep Vidal; Joana Nicolau; Fabiola Romero; Roser Casamitjana; Dulce Momblan; Ignacio Conget; Rosa Morínigo; Antonio M Lacy
Journal:  J Clin Endocrinol Metab       Date:  2008-12-23       Impact factor: 5.958

8.  Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass.

Authors:  Kirstine N Bojsen-Møller; Carsten Dirksen; Nils B Jørgensen; Siv H Jacobsen; Annette K Serup; Peter H Albers; Dorte L Hansen; Dorte Worm; Lars Naver; Viggo B Kristiansen; Jørgen F P Wojtaszewski; Bente Kiens; Jens J Holst; Erik A Richter; Sten Madsbad
Journal:  Diabetes       Date:  2013-11-15       Impact factor: 9.461

9.  Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans.

Authors:  Marzieh Salehi; Ronald L Prigeon; David A D'Alessio
Journal:  Diabetes       Date:  2011-09       Impact factor: 9.461

10.  Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

Authors:  Nils B Jørgensen; Carsten Dirksen; Kirstine N Bojsen-Møller; Siv H Jacobsen; Dorte Worm; Dorte L Hansen; Viggo B Kristiansen; Lars Naver; Sten Madsbad; Jens J Holst
Journal:  Diabetes       Date:  2013-05-06       Impact factor: 9.461

  10 in total
  12 in total

1.  Sleeve gastrectomy rapidly enhances islet function independently of body weight.

Authors:  Jonathan D Douros; Jingjing Niu; Sophia Sdao; Trillian Gregg; Kelsey Fisher-Wellman; Manish Bharadwaj; Anthony Molina; Ramamani Arumugam; MacKenzie Martin; Enrico Petretto; Matthew J Merrins; Mark A Herman; Jenny Tong; Jonathan Campbell; David D'Alessio
Journal:  JCI Insight       Date:  2019-03-21

2.  Postprandial hypoglycaemia after Roux-en-Y gastric bypass in individuals with type 2 diabetes.

Authors:  Daniela Guarino; Diego Moriconi; Andrea Mari; Eleni Rebelos; Daria Colligiani; Simona Baldi; Marco Anselmino; Ele Ferrannini; Monica Nannipieri
Journal:  Diabetologia       Date:  2018-10-12       Impact factor: 10.122

3.  The Effects of Bariatric Surgery on Islet Function, Insulin Secretion, and Glucose Control.

Authors:  Jonathan D Douros; Jenny Tong; David A D'Alessio
Journal:  Endocr Rev       Date:  2019-10-01       Impact factor: 19.871

4.  Comparison of Hormonal Response to a Mixed-Meal Challenge in Hypoglycemia After Sleeve Gastrectomy vs Gastric Bypass.

Authors:  Clare J Lee; Jeanne M Clark; Josephine M Egan; Olga D Carlson; Michael Schweitzer; Susan Langan; Todd Brown
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

Review 5.  Medical Nutrition Therapy and Other Approaches to Management of Post-bariatric Hypoglycemia: A Team-Based Approach.

Authors:  Nicole Patience; Amanda Sheehan; Cameron Cummings; Mary Elizabeth Patti
Journal:  Curr Obes Rep       Date:  2022-09-08

6.  Beta-cell sensitivity to glucose is impaired after gastric bypass surgery.

Authors:  Marzieh Salehi; Amalia Gastaldelli; David A D'Alessio
Journal:  Diabetes Obes Metab       Date:  2017-12-18       Impact factor: 6.577

Review 7.  Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies.

Authors:  Marzieh Salehi; Adrian Vella; Tracey McLaughlin; Mary-Elizabeth Patti
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

8.  Roux-en-Y Gastric Bypass Is Associated With Hyperinsulinemia But Not Increased Maximal β-Cell Function.

Authors:  Annette Georgia; Maria Cecilia Catilo Asnis; Gerardo Febres; Amanda Tsang; Marc Bessler; Judith Korner
Journal:  J Endocr Soc       Date:  2019-01-23

Review 9.  PYY, a Therapeutic Option for Type 2 Diabetes?

Authors:  Claudia Guida; Reshma Ramracheya
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-01-22

10.  Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production.

Authors:  Nicolai J Wewer Albrechtsen; Rune E Kuhre; Daniel Hornburg; Christian Z Jensen; Mads Hornum; Carsten Dirksen; Maria Svane; Lærke S Gasbjerg; Nils B Jørgensen; Maria N Gabe; Emilie Balk-Møller; Reidar Albrechtsen; Marie Winther-Sørensen; Katrine D Galsgaard; Felix Meissner; Tina Jorsal; Asger Lund; Tina Vilsbøll; Rasmus Eliasen; Kirstine N Bojsen-Møller; Thomas Idorn; Carolyn F Deacon; Filip K Knop; Mette M Rosenkilde; Bolette Hartmann; Bo Feldt-Rasmussen; Matthias Mann; Sten Madsbad; Jens J Holst
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.